<DOC>
	<DOCNO>NCT02132403</DOCNO>
	<brief_summary>This Phase Ib dose escalation study evaluate BTH1704 , monoclonal antibody target aberrantly glycosylated antigen Mucin 1 , Imprime PGG , glucan contain yeast essential trigger leukocyte-mediated cytotoxic response towards tumor cell , combination gemcitabine patient advance PDAC . The three intravenous drug take tandem 4 time 28-day cycle . The MAD BTH1704 ( BTH , 3 dose level ) combination gemcitabine ( Gem ) Imprime PGG ( I ) determine use standard `` 3+3 '' design . Treatment continue disease progression , unacceptable toxicity , physician discretion , patient refusal .</brief_summary>
	<brief_title>( PM-01 ) IMPRIME PGG® With BTH1704 Gemcitabine Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Milk fat globule</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Male female ≥ 18 year 2 . Histologically cytologically confirm adenocarcinoma pancreas , include pancreatic adenosquamous carcinoma , pancreatic anaplastic adenocarcinoma , pancreatic signet ring carcinoma , papillary mucinous carcinoma , acinar cell carcinoma , ampulla vater carcinoma , locally advanced ( able proceed surgery ) , recurrent , metastatic ( mixed adenocarcinoma pancreas acceptable invasive component predominantly adenocarcinoma ) 3 . Has measurable disease , define least 1 tumor fulfills criteria target lesion accord RECIST 1.1 4 . Has ECOG PS 0 , 1 , 2 5 . Has chemotherapy &gt; = 2 week 6 . Has patent biliary stent require biliary ductal obstruction , adequate nutritional intake , pain stable minimum 24 hr ( pain score ≤ 3/10 ) 7 . Has total bilirubin &lt; 2 mg/dL , AST ALT &lt; 3.0 × ULN &lt; 5 x ULN subject know hepatic metastasis 8 . Has serum creatinine &lt; 2.5 × ULN 9 . Has hemoglobin ≥ 9 g/dL , ANC ≥ 1.0 × 10^9/L , platelet count ≥ 100 × 10^9/L 10 . Must willing able comply study 11 . Has read , understood sign ICF 12 . Women childbearing potential must pregnant breastfeeding . In addition , medically acceptable method birth control must use total abstinence . Women postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) consider WOCP . 13 . Men surgically medically sterile must agree use acceptable method contraception . Male patient female sexual partner pregnant , possibly pregnant , could become pregnant study must agree use condom least 30 day last dose study drug . Total abstinence acceptable alternative . 14 . Prior systemic treatment metastatic disease permit , include targeted therapy , biologic response modifier , chemotherapy , hormonal therapy , investigational therapy . 15 . Availability tissue applicable ( primary tumor metastasis ) bank 16 . Willingness donate blood biomarker study 17 . Must receive least one prior systemic chemotherapy disease progress 1 . Has diagnosis resectable pancreatic adenocarcinoma 2 . Had surgery within 4 week prior study treatment 3 . Has either untreated symptomatic CNS mets 4 . Has know hypersensitivity BTH1704 , murine protein , component BTH1704 5 . Has know hypersensitivity baker 's yeast 6 . Has previous exposure Imprime PGG 7 . Has previously receive organ progenitor/stem cell transplant 8 . Has history blood clot , pulmonary embolism , DVT unless control anticoagulant treatment 9 . Has know history HIV positivity untreated &amp; uncontrolled hepatitis B C 10 . Has clinically significant infection 11 . Has severe , uncontrolled medical condition , include uncontrolled DM unstable CHF know suspect allergy study drug 12 . Other severe acute chronic medical psychiatric condition , laboratory abnormality may increase risk associate study participation 13 . Presence nonhealing wound , fracture , ulcer 14 . Has condition , opinion investigator , might jeopardize safety patient interfere protocol compliance 15 . Has mental medical condition prevents patient give informed consent 16 . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate gemcitabine drug formulate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas ( PDAC )</keyword>
	<keyword>mixed adenocarcinoma pancreas</keyword>
	<keyword>locally advanced</keyword>
	<keyword>recurrent</keyword>
	<keyword>metastatic</keyword>
</DOC>